AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05083260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE3107
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
Study NCT05083260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Hard gelatin capsule containing only common excipients for oral formulations
Study NCT06286540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphoblock
Description: 1 time per surgery with the exposition for 20 minutes.
Study NCT06286540 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 time per surgery with the exposition for 20 minutes.
Study NCT05091944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: web-based birth decision aid
Description: Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
Study NCT02841293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological mesh
Description: The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
Study NCT02841293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary perineal wound closure
Description: The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
Study NCT06320873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: archery respiratory parameters
Description: Evaluation of respiratory functions, respiratory muscle strength and shooting performance in archers
Study NCT05458219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI343
Description: IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
Study NCT05296096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein dosage and rehabilitation team delivered exercise prescription
Description: The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions.
Study NCT05296096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein dosage and rehabilitation team delivered exercise prescription
Description: The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions.
Study NCT05580978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM
Description: The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
Study NCT05580978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Participant's current prediabetes treatment.
Study NCT05629494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg, TID
Description: Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
Study NCT05629494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSA test
Description: PSA test will be repeated in 6 weeks
Study NCT05629494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSA test
Description: PSA test will be repeated in 6 weeks
Study NCT04852679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lanreotide autogel
Description: Administered as deep subcutaneous (SC) injections
Study NCT06304792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate FET in a stimulated or programmed cycle
Description: Patients will undergo FET in the cycle immediately following oocyte retrieval and a failed fresh embryo transfer or freeze all.
Study NCT05450003 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation
Description: irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
Study NCT06173635 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Maxi Move 5
Description: 4 comparative devices will be used to evaluate the MM5 device
Study NCT06295627 — intervention group
Intervention type: OTHER
Intervention: There were no interventions in retrospective analysis
Description: A retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. A single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.
Study NCT05248256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based radiation dose limitation to the vertebral bone marrow
Description: The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
Study NCT05971602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
Description: D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Study NCT05971602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
Description: P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Study NCT05971602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
Study NCT05971602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
Study NCT05971602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin (HR)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
Study NCT06221592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: defocus spectacle lenses
Description: To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
Study NCT06221592 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: defocus spectacle lenses
Description: To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
Study NCT05674916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound-driven diagnostic pathway
Description: Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
Study NCT06483048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MUC1-activated T-cells
Description: Given IV
Study NCT06483048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and possible ascites sample collection
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06483048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06483048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06276777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth varnish (PRG Barrier Coat from Shofu)
Description: Treatment of cervical dentin hypersensitivity with tooth desensitizers.
Study NCT06276777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth varnish (Clinpro white varnish 3M)
Description: Treatment of cervical dentin hypersensitivity with tooth desensitizers.
Study NCT05887167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cells added to planned CAR T
Description: Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
Study NCT06330792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bio-mechanical awareness
Description: Biomechanical awareness advices for physiotherapists during session: consist of group of awareness advices and McKenzie extension part method exercises to help physiotherapist working in correct position and consume his energy.
Study NCT06330792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercises
Description: Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area
Study NCT04779580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic
Description: Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
Study NCT04779580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcostal Nerve Block Using Local Anaesthetic
Description: Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
Study NCT05730244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cassia alata extract
Description: 1 ml Cassia alata extract
Study NCT05730244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml placebo solution
Study NCT05715489 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of pre and postoperative POP-Q values of the patients
Description: Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
Study NCT05715489 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of pre and postoperative PISQ-12 scores of the patients
Description: Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
Study NCT06452849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nervio-X
Description: An 8-channel TIS device developed by NEURODOME Corporation.
Study NCT05092243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT05092243 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT06381011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration
Description: The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
Study NCT06381011 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Local Vibration
Description: The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
Study NCT05017324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WGS DST strategy
Description: WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
Study NCT05142982 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
Study NCT05799664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLD
Description: Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
Study NCT05799664 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TLD procedure
Description: Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
Study NCT05799664 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care
Description: Patients will also receive standard of care that meet the recommendations of GOLD guideline.
Study NCT05799664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients will also receive standard of care that meet the recommendations of GOLD guideline.
Study NCT05157841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 266 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
Study NCT05157841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
Study NCT05157841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 133 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
Study NCT04662528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 1g capsules/day
Study NCT01122004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study NCT04662528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT9001 (omega-3 pentaenoic acid)
Description: 4 x 1g capsules/day
Study NCT05385952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATT-Patch
Description: GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver.
Study NCT05196048 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT05385952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil
Description: TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.
Study NCT05369208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avatrombopag Oral Tablet
Description: Avatrombopag 20 mg given once daily (initial dose). Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
Study NCT06550011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 Low Dose
Description: Low dose. lower than the safety factor of 10 as recommended by the FDA
Study NCT06550011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 Medium Dose
Description: Medium dose
Study NCT06550011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 High Dose
Description: High Dose
Study NCT04760730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength > 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box
Study NCT04760730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers
Study NCT06354335 — intervention group
Intervention type: OTHER
Intervention: Employees exposed to a major hospital reorganisation
Description: Occupational exposure